Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Sep 2025 value amounting to -90,572.03%.

  • Crinetics Pharmaceuticals' EBITDA Margin was N/A to -90,572.03% in Q3 2025 from the same period last year, while for Sep 2025 it was -21,868.72%, marking a year-over-year change of. This contributed to the annual value of -28,722.04% for FY2024, which is 2349849.00% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported EBITDA Margin of -90,572.03% as of Q3 2025, which was down 704.87% from -11,252.96% recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' EBITDA Margin peaked at -1,163.75% during Q1 2022, and registered a low of -90,572.03% during Q3 2025.
  • In the last 3 years, Crinetics Pharmaceuticals' EBITDA Margin had a median value of -13,808.27% in 2023 and averaged -22,585.28%.
  • Within the past 5 years, the most significant YoY rise in Crinetics Pharmaceuticals' EBITDA Margin was 739,241bps (2025), while the steepest drop was 1,593,236bps (2025).
  • Crinetics Pharmaceuticals' EBITDA Margin (Quarterly) stood at -6,193.51% in 2022, then slumped by 690,594bps to -16,363.58% in 2023, then plummeted by 1,356,743bps to -18,645.36% in 2024, then spiked by 739,241bps to -90,572.03% in 2025.
  • Its EBITDA Margin stands at -90,572.03% for Q3 2025, versus -11,252.96% for Q2 2025 and -26,519.39% for Q1 2025.